Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Kamat on a Molecular Definition of BCG Failure

February 26th 2013

Ashish M. Kamat, MD, from MD Anderson Cancer Center, discusses enhancing clinical trial recruitment through a novel definition of BCG therapy failure in patients with nonmuscle invasive bladder cancer.

Targeted Therapies, Multidrug Regimens, and Standardized Drug Development Efforts Needed in Nonmuscle-Invasive Bladder Cancer

February 26th 2013

Collaborative and standardized efforts to develop and evaluate novel drugs are necessary to ultimately provide effective long-term treatment for nonmuscle-invasive bladder cancer.

Regorafenib Approved to Treat GIST

February 25th 2013

The FDA approved regorafenib for the treatment of gastrointestinal stromal tumors that cannot be removed surgically and no longer respond to other FDA-approved treatments for the disease.

Dr. Gradishar on Enriching Targeted Therapy Trials

February 19th 2013

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, describes the need to enrich the patient population in a clinical trial that is investigating a novel targeted therapy.

Tandems of Targeted Therapy No Better Than Bevacizumab Alone in Advanced Renal Cell Carcinoma

February 16th 2013

Combination targeted therapy did not significantly extend progression-free survival compared with single-agent bevacizumab in patients with advanced renal cell carcinoma.

The Cost-Effectiveness of Targeted Therapies in NSCLC

February 13th 2013

Impact of EGFR Mutations on Treatment Decisions in NSCLC

February 13th 2013

Access to Molecular Testing Therapy in NSCLC

February 13th 2013

Personalizing the Treatment of Lung Cancer

February 13th 2013

Promising Emerging Classes of Therapies in NSCLC

February 13th 2013

Molecular Heterogeneity in Non-Small Cell Lung Cancer

February 13th 2013

Selecting Treatment for First- Line Non-Squamous NSCLC

February 13th 2013

Selecting a Laboratory for Molecular Testing in NSCLC

February 13th 2013

Rebiopsying and Molecular Testing in NSCLC

February 13th 2013

Molecular Testing and Actionable Targets in NSCLC

February 13th 2013

Best Practices in NSCLC Molecular Testing, Part II

February 13th 2013

Concurrent Versus Sequential Testing in NSCLC

February 13th 2013

Best Practices in NSCLC Molecular Testing, Part I

February 13th 2013

Introduction: Advances and Issues in NSCLC

February 13th 2013

Squamous Cell Carcinoma Treatment Options

February 13th 2013

x